A Louisiana man has filed a new breast cancer drugs lawsuit on behalf of a family member who suffered permanent hair loss due to Taxotere.

Plaintiff David A. has filed this breast cancer drugs lawsuit on behalf of Joann S. Joann allegedly suffered from breast cancer and was prescribed Taxotere to treat her cancer. According to this breast cancer drugs lawsuit, she took Taxotere from July 2014 to Nov. 2014.

The plaintiff in this breast cancer drugs lawsuit claims that Joann’s hair did not grow back after she used Taxotere to treat her breast cancer.

David’s breast cancer drugs lawsuit is joining the Taxotere MDL (multidistrict litigation) which will streamline the legal process.

This Taxotere breast cancer drugs lawsuit makes claims of failure to warn, negligence, negligent misrepresentation, fraudulent misrepresentation, fraudulent concealment and fraud and deceit.

The Dangers of Taxotere

Taxotere, one of the breast cancer drugs that Joann took to treat her breast cancer, is a popular drug manufactured by Sanofi Aventis. Taxotere, generically known as docetaxel, has been approved since 1996 by the U.S. Food and Drug Administration to treat breast cancer. Taxotere is often used in conjunction with other breast cancer drugs.

When a patient must undergo chemotherapy treatment to treat breast cancer using breast cancer drugs, that patient may expect some hair loss. Temporary hair loss is a common side effect of chemotherapy. Chemotherapy attacks quickly growing cells which is why breast cancer drugs can be effective against cancer. But breast cancer drugs also attack the quickly growing cells that cause hair growth. This is why chemotherapy breast cancer drugs also affect hair loss and growth in cancer patients.

Those who take breast cancer drugs expect their hair to regrow after treatment ceases. However, Taxotere patients have reported that their hair does not return, even after treatment is over.

When a woman is contending with an illness like breast cancer, it is already physically and emotionally trying. If patients, in addition to their illness, also do not see their hair return after breast cancer drugs treatment, the result can be devastating.

It is estimated that up to ten percent of Taxotere patients do not see a return of hair growth after they stop taking Taxotere. Taxotere can also be used to treat patients who suffer from lung cancer, prostate cancer, head cancer and neck cancer, but it is most commonly used to treat patients with breast cancer.

In 2015, nearly twenty years after Taxotere came on to the market, the FDA asked Sanofi Aventis to change the warning label on Taxotere. It now must include the fact that permanent hair loss is a possible risk for patients who take Taxotere.

However, the new warning allegedly came too late for many patients. Many patients believe that Sanofi Aventis either knew or should have known that their breast cancer drugs came with permanent hair loss risks. Many patients allege that Sanofi Aventis did not warn them about these risks and that they would have made a different choice regarding treatment if they had known.

This Breast Cancer Drugs Lawsuit is Case No. 2:18-cv-06038 in the United States District Court for the Eastern District of Louisiana.